&
)
#
' $
$
(
%
!
!
"
%
!
"
" #
$
#
#
"#
#
#
"
'
"
#(
" #&
)
*+,- ./0
34
+1
2++ !
355
%
"6
73
+%%89%%
: #
9
(
; 7
!"# $!% !
•
•
•
•
•, •
•, /
"
"
!"# $!% !
2
(
#
3 7
+
9 3
*
+
! +
+
$
. $
-
+
/
,
+
$
/
/
$)
376 7
?
?
@ ?
6
5
+%%%
+%%C
5
7 " A7
01222 " 12234
/
#
, '
(
$
/
5
5
7
7AB
07888 " 12774
6
7888 % 1272
#
#
2
./+/ 9./++
.//= > ./++
"6
7 < "$ %& ' ' ( "$ )) !( (
* ( +' !( " )!( (
, "
)!& ! % & " ! %
(-& " ( ( )+ " *
"6
( %(
7<
) ." '
/!( " ()+
( +%
(
F76
3A 7 3 3
E 7;
E 6
3
E ; 3
3 3
F ? ?
37E? 3
35 76 3 5A
6
37 ? 6
7?
"6
37
?
@
A 3
73
37
FJ
"6E D 3
" , ,!
' EA
?6 ?
7 6 BA
3
6 3
73
3
; 37
@
3<
3
5 6 @
?
9
D6
0 !"# $!%
;
5 6
?
6?
37E? 3
A
3
"6E D 3
" , %!
; E
#E7
3
H6
E?
I6D 3
6
3
34
" 6G3 7 3
7 37
3
7
3E376 7 5 6B 7
"# :
L M '
N
(
' P
#(
5 6 @
#
#
:
:
" #
./// >.//8
#
K1
O
SALAMANCA
MADRID
TENERIFE
MERIDA
GUATEMALA
PANAMA
BOGOTA
IQUITOS
ANTOFAGASTA
SANTIAGO
(-& "
(
%1
"!(!&
!"# $!%
; 7
BELO HORIZONTE
ASUNCION
)%+3
"6
6
(& !' +& $ )
LA PAZ
7
7
E7 76
N
; N
" 6A ? ./// > .//=
D N(E 7
"
G
%+&
(-& "
!% % # !" )!& ! $+ " ' "+ ,!( # " (
" ) ") %# "!( "
% ( %!( 1 " $2"# )!(
(
9
9
9
9
9
;
;
;
;
;
63 ?
63 ?
63 ?
63 ?
63 ?
?? "
G9
?? # 3 6
?
6?
?
?
??
6 3
#"
?6J3>
D N
7
0#+1 " "( ( 1 0
" & "( (
0& 5 ) "
0 & 3!" "( (
0, () %
04% 3
"( (
3B
@
F
@
? 5 7@
3
355
(-& "
"
(
#
(
#
" I
% -'
!& !" (
%
(-& "
!& !" (
( !)% - '
%1
"!(!&
'
37
7
(-& "
+%!
(-& "
0 & 3!" "( (
%1
0& 5 ) "
"!(!&
-1 !& !" (
"'! %1
"+&
"6
37
7
04% 3
""
04% 3
? B ? B6
"( (
"( (
9 G;
" 3 9 G6QE NL
E D
A ?
; 63 ? ? E7@
?
5 4 N JF N+%%1
3
34
3 3ON
# 3E 7 ? 3 (
6 3?
"6
7 R3QE ? D7
@
; E @
? E ; 3
7 3 75 6 3 7 6 3 ./// >
/8!
Laboratorio Sustancias Leishmania Chagas Epi Chagas Tripo Malaria vitro Malaria vivo
Antofagasta
36
1
6
0
3
2
Bogotá
83
28
4
2
8
0
Guatemala
52
21
5
3
0
0
México
81
12
7
11
0
Panamá
17
13
0
2
1
0
Salamanca
118
34
34
28
18
3
Tenerife
28
0
0
0
16
0
415
109
56
35
57
5
Total
# #
#
# 3E 7 ? 3 ( D 3 ?
D 6 @ <
; E
3 75 6 3 7 6 3 " , %!6
% 7 (-& " 1 - # (
2:%2;
#
5
=3
>
, / . %(
@ %
' A
2;%<
2<%28
28%72
71
1=
37
7=
<=
7;
::
17
<3
?
73
73
++%
S%
;
1;
+S=
CC
7:1
<=
37
7=
1:
728
;
1;
=0/
'
#(
)
)
,- ./1 +1 2++ !
µ U
1/T+//µ
,- .SS
+C
2+1
.!
,- +%% += 2+S !
µ U
1/V.1µ
)
)
,- .81 +0 2+8
µ U
1/V.1µ
&6
G7
? ' EA
6
JE7
!
3? .//+ 6 D H
3
!"# $!% 9 ;
7
N
'* 788C'DE
'* #7=F7;B
7 9 F76
6D H ?
5
@
6D H ?
D 676
, &
B
B
#
3
7
?6 ?
J7 ? 3 6
7 6GB
35 76 3 @5 3
3
B
E 7; " , %! ?
7
,
'
A
; 7
7
% > .W 9 =
8 >0 9 C
8W > S 9 =W
=
S
8
%
=W
.W
8W
C
S
=W
0
8
%
=
1
+W
.
+/
#7? F77 B
C'ED G 12?
#7: F73 B H
C'ED G 13?
8
8
%
%
C
8W =W
+W
8
=
%
.W
1W
67
; 63 ? ? ?
? 3
7
E
3! 5 6( >
N
6B N 35 X
C'(D7EG 12: 0
+1
2++ 4
5 3 @ ?
5 6 @
C'(D7EG 13: 0
+0
2+8
4
1%(6
E @ + 2
76 ?
52 8 /
F76 7 52 S /
%
-;?2#
5 3 @ ?
"6 5 7 6.9B
.C .Y ! ? 35EJ3 ?
9QE
5 6( 9
C'(D7EG 13: 0
+=
2+S 4
+0
2+8
4
+C
2+1
.4
+1
2++ 4
C'(D7EG 12: 0
C'(D7EG 1;< 0
C'(D7EG 122 0
+1
2+%
4
C'(D7EG 132 0
2+8
4
+.
C'(D7EG 7;1 0
C'(D7EG 32< 0
+%
2+S
84
"
: #
#
:<%;1I
+1
2++ 4
C'(D7EG 122 0
+=
<:%87I
C'(D7EG 12: 0
2+S 4
+0
2+8
4
8?%88I
C'(D7EG 132 0
+1
2+%
4
4
2+8
+.
C'(D7EG 7;1 0
C'(D7EG 13: 0
C'(D7EG 1;< 0
+C
2+1
.4
C'(D7EG 32< 0
+%
2+S
84
Biological Activity Aspects
Leishmania amazonensis PH8
Immunological Aspects
Wenner Gren Institute of Immunology
Stockholm University
Our results showed that the
alkaloid extract of Evanta was not
directly stimulating B cells, T cells
or J774 macrophages, but it
interfered with the activation of
both mouse and human T cells, as
seen by the reduction of cellular
proliferation and in vitro induced
production of IFN-γγ.
It was established, as well, that the
effect of CAT on the parasite was
intense at 10 ug/ml and that it was
stronger than the effect of the
purified alkaloid, 2-phenylquinoline.
80
IC50 ug/mL
70
60
48.6
50
40
31.3
30
20
10
0
2FQ
S.Y
CAT
+//Y
CAT-2FQ
Leishmania brasiliensis M2903
200
193.7
180
160
IC50 ug/mL
Our results suggest that Evanta
can control the chronic
inflammatory reaction and
therefore may contribute to the
reduction of the pathology in the
lesion.
83.1
90
140
120
100
80
51.3
60
32.3
40
20
0
2FQ
CAT
CAT-2FQ
.CY
$
.//. > .//%!
2 #
$<
+8Z10 1CSW
[ 0CZ// 8/CW
.%8 3
2
<
#
" ?6
#
#
<
4EQE
+1Z.+ 8/.W
[ 0SZ./ .8CW
1+= 3
7 2E
# 3E 7 ? 3 ?
6D H
D 6
@
9
6B
8< :I
8: 2I
8: 8I
8: 1I
8 +"
'
3
#(
9+
376A
O
*
.//.9.//S
377E7 ?
; 37
3 G6
QEA
3>
• ; 63 ? ? " E D 7 6N E 7 ? ?
6
9
? ? # +=1 9 # N E E3 N 6
9
76 ?
; 37
3
7B 3 ? :E 7 9
9
•
)
)
,- ./1 +1 2++ !
µ U
1/T+//µ
,- .SS
+C
2+1
.!
,- +%% += 2+S !
µ U
1/V.1µ
)
)
,- .81 +0 2+8
µ U
1/V.1µ
:
A
L
" #
K
#
•
•
•
•
K
1/ T +/ U\
+/ U\
+/ U\
T +/ U\
O
A
1< !
A
82 !
ìndice de Lesões (ULI)
ULI (ìndice de Lesões Ulcerativas)
30
25
20
Controle
50 mg/kg
15
125 mg/kg
250 mg/kg
Omeprazol 30 mg/kg
10
5
0
Contorções abdominais induzidas pelo ácido acético, i.p.
45
40
50
DI50 = 20,34 (15,81 - 26,17) mg/kg
45
35
30
40
n. co ntorções
37E? 3
5
76 3
(6E5
; > 7H
"6 B ? 6
4
35
44,0%
**
30
25
25
56,6%
**
20
64.4%
**
20
62,1%
**
15
10
15
10
5
5
0
controle
0
Controle
10 mg/kg
30 mg/kg
50 mg/kg
50 m/kg
Galipea, via oral
%
&
" !(
" )!(
,(0
37 7 3
0 & 3!" "( (
E63 ? "6
"6
7<
6 76
@ QEA
ND
? 37 7 3?
76 7
7 ?
E63
@
B6
!"# $!%
3 34
73
2 9 .//S
@
?
; 7 !5 6
33
3
Numero de casos de leishmaniasis reportados en 2006
!
"
!
$
$
%
&
'
)
##
(#
!
*
$
#
$+
" ,
+
+"
&
'
-
.
'
,
.
%
/ 0
&
+ ,
+,
2
'
%
1++0
&
!.
#
&
'
#
&
'
*#
+"
3
+,
)
'
"
&
'
,
&
'
$
)3
+
--#
**
&
,
#
&
'
(
-(
#(
!!
(
(*
#*
(
#
#
#
#(
#
Programa Nacional de Leishmaniasis
"
"#$ %$&'$
?2%;?I
C'(D7EG 12: 0
+1
12%=?I
2++ 4
#?2 J?2
K )
+=
C'(D7EG 122 0
2+S 4
#?2 12
J ?2
K )
(
C'(D7EG 13: 0
+0
2+8
4
C'(D7EG 1;< 0
+C
2+1
.4
+.
2+8
4
“Estudios químicos, biológicos y farmacológicos de Galipea
longiflora, Krause”. A. Giménez, G. Ruiz, J.A. Avila, et al.
Revista Boliviana de Química. Vol 22 No 1, 94-107, (2005).
C'(D7EG 7;1 0
#?2 12
J ?2
K )
7%=I
C'(D7EG 32< 0
+%
2+S
84
Programa UMSA-ASDI-SAREC- Período 2004 – 2010
Proyecto: Enfermedades Infecciosas
”Estudios Clínicos Fase II de la Evanta en el
Tratamiento de Leishmaniasis cutanea”
•Universidad Mayor de San Andrés - UMSA
•Facultad de Ciencias Farmacéuticas y Bioquímicas
•CIDME-SELADIS –IIFB
•Universidad de Estocolmo
•Departamento de Inmunología
•Hospital de Palos Blancos
•Centro de Estudios
•Proyecto OSCAR
•Seguimiento de pacientes
•Consejo Indigena de los Pueblos Tacana – CIPTA
•Comunidad de Santa Rosa de Maravilla
#
<
•,
!
>
;2I
/
•(
/
/
$
-
/
6
!
/
=
9
.
+
"
+
N #
*
#
(
9(
"6
?
D6 ?
5 ?
(-&
5 ?
(-&
6B6
"
& 3!" "( (
6B6
" 4% 3 "( (
3
5 3
R
6
+
+
=
#D 6 79
@?
+
2
2
E 6
U #US0U
9/+.
U #US1U .%/8
.
2 35 7 ?
#D 6 7
8
8
+
3
39
"
+
9//.
6
E7G
6
6
6
2 35 7 " 3
3
6
Actividad antiparasitaria de Alcaloides Totales de
Corteza de Galipea longiflora sobre 5 cepas
nativas y 2 cepas de referencia
40
CI50ug/m
L(CAT)
"
5 ?
3@
35
LB2
30
LC3
25
LB3
LD1
20
M2903
15
Lma
10
LBTE-002
5
0
1
Diferentes cepas de
Leishmania (promastigotes)
:
;
< % ) %3 ) ." 9+ & )
4 ! .# ) 1 $ %& )! .# ) '
!( ) ! ' ( !
('
!"# $!% = , " >
%
% & " !'
(
(-& " ( (*
5 B
@ 5 6" #
76 B 6 3 3 ? 3
7
E
6S #
4% 3
"( (
"6
"
7<
( % ( ) ." '
" ()+ ( +%
/!(
(
" #&
#
@
7 ? "6 7
6 3U2
73
38 3 E
"6
3
?
#
#
" # "#
#
" #
A7E ? "6
,A
"# :
N(
.//%
"# ( #
7 <L
6 M !
/
)
(
>
$
6
Título abreviado del proyecto: Extractos Acuosos de Evanta
Unidad Proponente: Instituto de Investigaciones Fármaco Bioquímicas:
Unidad de Química Farmacéutica
I B ? "6
3E
4 6 3
D 676
7*
E 7 ? ? <#
4 6 3
$
4 ? <
0" "
.
/
0, %& )+ %(
0" "
<27K72K28
,
&6 3 56
7
!
5
3
7
1
3
=
N
N
N
N
#
#
#
<32K28K72
B
! $
(
$ ,A
!
$F
E6
6A ? "6
@ * 71
=
7<
3 3
• E7??
• 377E7 ?
• D6 3
• 3E ?
3
6
JE7 3
QEA
; 37
3 G6
QEA
3?
3?
3 #E6 >
E ? ? 4 6 3
3>
3>
#
6
? 7!
6 ( J !
6 # " 66 !
"6 B 2 # 3!
( %+) +% '
%!1 ) !
(
%(
) ." '
/!( " ()+
)
M !
,
#
6 $#
6
O
/
#
/
,
03 L
/
$,
/
#
7? !
6
$
D ?
; 7
3E
4 6 3 0:2 . 4
,
,
,
#
/
6
6
/
(
6
5
$
#
( +%
H (# 5 #
$
/
71 !
. 4
6
$
D
,
?
3 ? 0=7 . 4
,
60=; . 4
#
@
7 ? "6 7
6 3U2
73
38 3 E
"6
?
3
3E
# 3E 7 ? 3 "6
4 6 3
6 3?
76
./+/
@37
1& "!
(" "
+1 ?A 3
.C ?A 3
37 @ <
!) !% !"!%( +(
X 6<
!" !#
! -+9+
%( !
!% " +(! ' ( ) ( & ' ) " (
& 3." ) (7' )+ %'! )!( +&4% ( 1
)!"!) & " !( % ' ) !" ( '
+ +%
35
3
) "
?
3 75 6 3 7 6 3
?
6
5
BE 6
; 37 ? 3N? 3 66 ? 3
; ? ? 3N ? 7 37E? 3
E 7? 3 5
6 3 A
35 6
E7??
3 6
JE7 3
QEA
3?
+?
7ED6 ? ./+/
QE 5 ?
6D H ?
5
#
F
,
&
# /!
' EA
<
B
P ,
O
#
)
)
,/
7
'
'
,
'
$
5 <
0
0#
)
(
6D H
7E
7; ? ?
,- ! (
4
4
6
0
0 '( 4
0# ' ( 4
0 '( 4
A
'(
7
'(
4
,
O
@
'(
'(
A <
)
0
4
" 6G3 7 3 7 37
3<
'
) (
(
'
,
#
)
Q
$L
,
,
,
O
'
,
O
R @ ,
O '
,
B
,
O
)
(#
#
#